| Customization: | Available |
|---|---|
| Function: | Cardiovascular Agents |
| Certification: | GMP, FDA |
|
Still deciding? Get samples of US$ 5/g
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Introduction
CAS NO: 137862-53-4
Chemical Name: N-(1- valeryl)-N-[4-[2-(1H- tetrazole -5- pyridyl) phenyl] phenmethyl]-L- Valine
Chemical Classification: Pharmaceutical apis
MF: C24H29N5O3
Assay: 98.-102%
Quality Standard: Meets EP6
Appearance: white or almost white crystalline powder
Package: In 25kg/ fiber drum inner polythene bags
Storage: Cool, dry, room-temperature and well-closed container
Valsartan is used clinical for receptor antagonist of angiotensin AT1, has good effect to the different degree of hypertension patients who used other antihypertensive drugs without efficacy , is a new generation of highly efficient antihypertensive drugs.
White or almost white crystalline powder, odorless, slightly moist. easily dissolved in methanol and ethanol , sparingly soluble in ethyl acetate, slightly soluble in dichloromethane, almost insoluble in water.
Function
Valsartan is used clinical for receptor antagonist of angiotensin AT1, has good effect to the different degree of hypertension patients who used other antihypertensive drugs without efficacy , is a new generation of highly efficient antihypertensive drugs.
Application
Valsartan (Angiotan) is an angiotensin II receptor antagonist (more commonly called an "ARB", or angiotensin receptor blocker), with particularly high affinity for the type I (AT1) angiotensin receptor. By blocking the action of angiotensin, valsartan dilates blood vessels and reduces blood pressure.[1] In the U.S., valsartan is indicated for treatment of high blood pressure, congestive heart failure (CHF), or post-myocardial infarction (MI).[2] In 2005, Angiotan was prescribed more than 12 million times in the United States and global sales were approximately $6.1 billion in 2010.[3]
A study released by the Journal of Clinical Investigation in 2007 found some efficacy in the use of valsartan in the treatment and prevention of Alzheimer's disease (in a mouse model) although such use is considered to be highly experimental.
Specification
|
Item |
Specification |
Result |
Test Method |
|
Active Ingredeints |
|
|
|
|
Assay |
98.5% |
99.5% |
HPLC |
|
Physical Control |
|
|
|
|
Identification |
Positive |
Conforms |
TLC |
|
Appearance |
white crystalline powder |
Complies |
Visual |
|
Odor |
Characteristic |
Complies |
Organoleptic |
|
Taste |
Characteristic |
Conforms |
Organoleptic |
|
Sieve Analysis |
100% pass 80 mesh |
Complies |
80 Mesh Screen |
|
Loss on Drying |
5% Max |
3.37% |
5g/105C /5hrs |
|
Solubility Solubility |
in water |
Conforms |
Visual |
|
Ash |
3% Max |
2.84% |
2g/525C/5hrs |
|
Chemical Control |
|
|
|
|
Sulphate |
0.5% Max |
Complies |
2g/525C/5hrs |
|
Insolubles In Ethanol |
10ppm Max |
5.3ppm |
|
|
Ethanol Resides |
0.2% Max |
Complies |
|
|
Arsenic (As) |
NMT 2ppm |
Conforms |
Atomic Absorption |
|
Cadmium(Cd) |
NMT 1ppm |
Conforms |
Atomic Absorption |
|
Lead (Pb) |
NMT 2ppm |
Conforms |
Atomic Absorption |
|
Chlorate (Cl) |
NMT 1ppm |
Conforms |
Atomic Absorption |
|
Phosphate Organics |
NMT 1ppm |
Conforms |
Gas Chromatography |
|
Heavy Metals |
20ppm Max |
Complies |
Atomic Absorption |
|
Pesticides Residues |
NMT 1ppm |
Conforms |
Gas Chromatography |
Packing & Storage
|
Packaging Detail |
0.5kgs/Al-foil bag 1.0kgs/Al-foil bag 2.0kgs/Al-foil bag 5.0 kgs/Al-foil bag 25.0 kgs/drum or upon customers' request. |
|
Storage |
Store in a well-closed container away from moisture |
|
Shelf Life |
2 years if sealed and store away from direct sun light. |
|
Delivery Detail |
within 3 days after get the payment |
){kind=link}